Categories: BioTechLearnResearch
RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness. Founded on pioneering research from the Institute of Molecular and Clinical Ophthalmology Basel (IOB), RhyGaze aims to restore vision and transform the lives of patients worldwide. IOB scientists Drs. Botond Roska, Bence György and Charles Gubser are the scientific founders of RhyGaze. The name RhyGaze derives from the Basel-German word for the Rhein (Rhy), on the banks of which the IOB is located. Learn more at www.rhygaze.com.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.01.2025 | Series A | $94.27M | - |
Mentions in press and media 4
| Date | Title | Description |
| 15.01.2025 | RhyGaze raises CHF 86 million to advance gene therapy for retinal diseases |
RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, who is a scientific co-founder of R... |
| 13.01.2025 | RhyGaze Closes USD 86M Series A Funding | RhyGaze, a Basel, Switzerland- and Philadelphia, PA-based biotechnology company developing gene therapies for retinal diseases, raised USD 86M in Series A funding.
The round was led by GV (Google Ventures), alongside Arch Venture Partners, ... |
| 13.01.2025 | RhyGaze: $86 Million (Series A) Raised To Develop Gene Therapies For Retinal Diseases | RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, announced that it has raised a Series A funding round of $86 million. The funding round was led by GV (Google Ventures), alongside Arch Venture Partners, F-... |
| - | Rhygaze | “RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.” |
Reviews 0